On Demand 2025 Saturday PM General Sessions

This course contains the following sessions from Saturday's afternoon program:

  • Beta-Lactam Allergies: More Than Penicillin
  • Editor’s Choice: Best Articles from Annals of Allergy, Asthma & Immunology
  • Jeopardy - What’s That Rash?
  • Navigating Current Treatments for Food Allergy
  • Food Allergy Management: An Evolving Landscape
  • I-EEEE-I So Many Rashes: Dermatologic Findings in Inborn Errors of Immunity in Allergy Clinic

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 9.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Discern the spectrum of hypersensitivity reactions associated with biologic agents, including IgE-mediated and non-IgE-mediated presentations.
  • Recognize the clinical and financial implications of beta-lactam allergies, including failure to remove unnecessary antibiotic allergy labels.
  • Develop an evidence-based approach to evaluating non-penicillin beta-lactam antibiotic allergies.
  • Provide education to primary care physicians and hospitalists to assess risk and de-label beta-lactam allergies outside of allergy clinic.
  • Identify safe biologics to use with live vaccines.
  • Outline considerations for epinephrine administration recommendations
  • Consider future applications of gene therapy
  • Distinguish and differentiate terms used to diagnose various skin conditions.
  • Recognize common and similar patterns of skin disease.
  • Formulate a treatment strategy for dermatologic diseases.
  • Identify the right patient for each treatment.
  • Effectively employ considerations of weight, allergen testing and other therapeutics.
  • Detail the role treatments can play in optimum patient care. Support treatment options that benefit quality of life.
  • Identify the right patient for each treatment.
  • Effectively employ considerations of weight, allergen testing and other therapeutics.
  • Detail the role treatments can play in optimum patient care. Support treatment options that benefit quality of life.
  • Identify benefits, risks and practical applications of biologics as monotherapy or in combination with oral immunotherapy in the food allergy clinic.
  • Analyze the use of OIT in the infant and toddler population, including risks, benefits and patient-related outcomes.
  • Evaluate available guidance on the use of omalizumab in the allergy clinic. Differentiate alternative routes of epinephrine administration for food-induced anaphylaxis.
  • Identify atopic conditions seen in allergy clinic, and when to consider IEI.
  • Promote appropriate diagnostic testing for IEI based on skin manifestation given high index of suspicion.
  • Describe the treatment options based on the skin findings seen for IEI in allergy clinic.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Attendance
  • 9.00 CBRN
Course opens: 
11/24/2025
Course expires: 
12/07/2028
Part of: 
On Demand ACAAI 2025 Annual Scientific Meeting
Rating: 
0

Thanaporn Ratchataswan, MD
Anna R. Wolfson, MD, FACAAI
David A. Khan, MD, FACAAI
Kimberly G. Blumenthal, MD, MSc, FACAAI
Larry Borish, MD, FACAAI
Matthew Greenhawt, MD, MBA, MSc, FACAAI
Jay A. Lieberman, MD, FACAAI
Anne K. Ellis, MD, MSc, FACAAI
Dawn Merritt, DO, FAOCD
Rachel L. Schreiber, MD, FACAAI
Brian P. Vickery, MD
Julie Wang, MD, FACAAI
Jonathan M. Spergel, MD, PhD, FACAAI
Anna H. Nowak-Wegrzyn, MD, PhD, FACAAI
Aikaterini Anagnostou, MD, MSc, PhD, FACAAI
Philippe Bégin, MD, PhD
Edwin H. Kim, MD, FACAAI
Vikash S. Oza, MD, FAAD
Karin Chen, MD
Alexandra Freeman, MD

Available Credit

  • 9.00 AMA PRA Category 1 Credit™
  • 9.00 Attendance
  • 9.00 CBRN
Please login or create an account to take this course.